US2023159656A1PendingUtilityA1
Anti-steap1 antigen-binding protein
Est. expiryJul 2, 2038(~11.9 yrs left)· nominal 20-yr term from priority
Inventors:Olivier Nolan-StevauxCong LiChristopher MurawskyBenjamin M. AlbaNeeraj Jagdish AgrawalKevin GrahamJennitte Leann Stevens
A61K 40/4274A61K 40/11A61K 2239/31A61K 2239/38A61K 2039/5158C07K 2317/92C07K 2317/73C07K 2317/31A61P 13/08C07K 16/3069C07K 16/2818C07K 16/2809C07K 2317/622A61P 35/00C07K 2317/33C07K 2317/24A61K 2039/505A61K 2039/6056C07K 2317/32C07K 2317/565C07K 2317/34C07K 16/18
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
Claims
exact text as granted — not AI-modified1 . An antigen-binding protein that binds STEAP1 of SEQ ID NO: 2 and comprises:
(a) heavy chain CDRs comprising amino acid sequences set forth in vhCDR1 SEQ ID NO: 14, vhCDR2 SEQ ID NO: 15 or vhCDR2 SEQ ID NO: 21, and vhCDR3 SEQ ID NO: 16 and (b) light chain CDRs comprising amino acid sequences set forth in i) vlCDR1 SEQ ID NO: 11, vlCDR2 SEQ ID NO: 12, and vlCDR3 SEQ ID NO: 13.
2 . An antigen-binding protein that binds STEAP1 of SEQ ID NO: 2 and comprises CDR sequences
a) vlCDR1 comprising SEQ ID NO: 30, vlCDR2 comprising SEQ ID NO: 31, and vlCDR3 comprising SEQ ID NO: 32, and b) vhCDR1 comprising SEQ ID NO:33, vhCDR2 comprising SEQ ID NO: 34, and vhCDR3 comprising SEQ ID NO: 35.
3 . The antigen-binding protein of claim 1 , comprising vhCDR1 comprising SEQ ID NO: 14,
vhCDR2 comprising SEQ ID NO: 15, vhCDR3 comprising SEQ ID NO: 16, vlCDR1 comprising SEQ ID NO: 11, vlCDR2 comprising SEQ ID NO: 12, and vlCDR3 comprising SEQ ID NO: 13.
4 . The antigen-binding protein of claim 1 , comprising
vhCDR1 comprising SEQ ID NO: 14, vhCDR2 comprising SEQ ID NO: 21, vhCDR3 comprising SEQ ID NO: 16, vlCDR1 comprising SEQ ID NO: 11, vlCDR2 comprising SEQ ID NO: 12, and vlCDR3 comprising SEQ ID NO: 13.
5 . (canceled)
6 . The antigen-binding protein of claim 3 , comprising a variable heavy domain comprising an amino acid sequence at least 90% identical to SEQ ID NO: 182.
7 . The antigen-binding protein of claim 3 , comprising a variable light domain comprising an amino acid sequence at least 90% identical SEQ ID NO: 183.
8 . The antigen-binding protein of claim 3 , comprising a variable heavy domain comprising an amino acid sequence at least 90% identical SEQ ID NO: 182 and a variable light domain comprising an amino acid sequence at least 90% identical SEQ ID NO: 183.
9 . The antigen-binding protein of claim 3 , comprising a variable heavy domain comprising SEQ ID NO: 182 and a variable light domain comprising SEQ ID NO: 183.
10 . The antigen-binding protein of claim 4 , which comprises a variable heavy domain comprising an amino acid sequence at least 90% identical to SEQ ID NO: 184.
11 . The antigen-binding protein of claim 4 , comprising a variable light domain comprising an amino acid sequence at least 90% identical SEQ ID NO: 183.
12 . (canceled)
13 . The antigen-binding protein of claim 4 , comprising a variable heavy domain comprising an amino acid sequence at least 90% identical SEQ ID NO: 184 and a variable light domain comprising an amino acid sequence at least 90% identical SEQ ID NO: 183.
14 . The antigen-binding protein of claim 4 , comprising a variable heavy domain comprising SEQ ID NO: 184 and a variable light domain comprising SEQ ID NO: 183.
15 . The antigen-binding protein of claim 1 , wherein the antigen-binding protein is an antibody.
16 . The antigen-binding protein of claim 15 , which is a monoclonal antibody, a chimeric antibody, or a humanized antibody.
17 . The antigen-binding protein of claim 1 , wherein the antigen-binding protein is an antigen-binding antibody fragment.
18 . The antigen-binding protein of claim 1 , comprising a single chain antibody.
19 . A pharmaceutical composition comprising the antigen-binding protein of claim 1 and a physiologically acceptable carrier.
20 . (canceled)
21 . A method of treating cancer, the method comprising administering to a subject in need thereof the antigen-binding protein of claim 1 .
22 . The method of claim 21 , further comprising administering to the subject an anti-PD-1 antigen-binding protein.
23 .- 26 . (canceled)
27 . The method of claim 22 , wherein the anti-PD: 1 antigen-binding protein comprises a vhCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 189 a vhCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 190, a vhCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 191, a vlCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 192, a vhCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 193, and a vl CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 194.
28 . The method of claim 27 , wherein the anti-PD: 1 antigen-binding protein comprises a heavy chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 195 and a light chain variable domain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 196.
29 . The method of claim 28 , wherein the anti-PD-1 antigen-binding protein comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 195 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 196.
30 . The method of claim 27 , wherein the anti-PD-1 antigen-binding protein is an antigen-binding antibody fragment.
31 . The method of claim 27 , wherein the anti-PD-1 antigen-binding protein is an antibody.
32 . The method of claim 27 , wherein the anti-PD-1 antigen-binding protein is a monoclonal antibody, a chimeric antibody, or a humanized antibody.
33 . The method of claim 27 , wherein the anti-PD-1 antigen-binding protein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 197 and a light chain comprising the amino acid sequence of SEQ ID NO: 198.
34 . The method of claim 21 , wherein the cancer is prostate cancer.
35 . The method of claim 21 , wherein the cancer is Ewing sarcoma.
36 . A polynucleotide comprising a nucleic acid sequence encoding the light chain variable domain and/or heavy chain variable domain of the antigen-binding protein of claim 14 .
37 . An expression vector comprising the polynucleotide of claim 36 .
38 . A composition comprising a polynucleotide comprising a nucleic acid sequence encoding the light chain variable domain of the antigen-binding protein of claim 14 and a polynucleotide comprising a nucleic acid sequence encoding the heavy chain variable domain of the antigen-binding protein of claim 14 .
39 . A method of making an antigen-binding protein, the method comprising contacting a host cell with the composition of claim 38 under conditions that allow expression of the light chain variable domain and the heavy chain variable domain.
40 .- 79 . (canceled)
80 . The antigen-binding protein of claim 1 , which is a Fab antibody fragment.
81 . The antigen-binding protein of claim 3 , which is a Fab antibody fragment.
82 . The antigen-binding protein of claim 81 , which is attached to a detectable label.
83 . The antigen-binding protein of claim 82 , wherein the label is radioactive.
84 . The antigen-binding protein of claim 4 , which is a Fab antibody fragment.
85 . The antigen-binding protein of claim 84 , which is attached to a detectable label.
86 . The antigen-binding protein of claim 85 , wherein the label is radioactive.
87 . The antigen-binding protein of claim 8 , which is a Fab antibody fragment.
88 . The antigen-binding protein of claim 87 , which is attached to a detectable label.
89 . The antigen-binding protein of claim 88 , wherein the label is radioactive.
90 . The antigen-binding protein of claim 9 , which is a Fab antibody fragment.
91 . The antigen-binding protein of claim 90 , which is attached to a detectable label.
92 . The antigen-binding protein of claim 91 , wherein the label is radioactive.
93 . The antigen-binding protein of claim 13 , which is a Fab antibody fragment.
94 . The antigen-binding protein of claim 93 , which is attached to a detectable label.
95 . The antigen-binding protein of claim 94 , wherein the label is radioactive.
96 . The antigen-binding protein of claim 14 , which is a Fab antibody fragment.
97 . The antigen-binding protein of claim 96 , which is attached to a detectable label.
98 . The antigen-binding protein of claim 97 , wherein the label is radioactive.
99 . A method for detecting STEAP1 in a subject, wherein the method comprises administering to the subject the antigen-binding protein of claim 82 and detecting the label.
100 . The method of claim 99 , wherein the detection of the label is by positron emission tomography.
101 . A method for detecting STEAP1 in a subject, wherein the method comprises administering to the subject the antigen-binding protein of claim 85 and detecting the label.
102 . The method of claim 101 , wherein the detection of the label is by positron emission tomography.
103 . A method for detecting STEAP1 in a subject, wherein the method comprises administering to the subject the antigen-binding protein of claim 88 and detecting the label.
104 . The method of claim 103 , wherein the detection of the label is by positron emission tomography.
105 . A method for detecting STEAP1 in a subject, wherein the method comprises administering to the subject the antigen-binding protein of claim 91 and detecting the label.
106 . The method of claim 105 , wherein the detection of the label is by positron emission tomography.
107 . A method for detecting STEAP1 in a subject, wherein the method comprises administering to the subject the antigen-binding protein of claim 94 and detecting the label.
108 . The method of claim 107 , wherein the detection of the label is by positron emission tomography.
109 . A method for detecting STEAP1 in a subject, wherein the method comprises administering to the subject the antigen-binding protein of claim 97 and detecting the label.
110 . The method of claim 109 , wherein the detection of the label is by positron emission tomography.
111 . The antigen-binding protein of claim 1 , which is a F(ab′)2 fragment.
112 . The antigen-binding protein of claim 3 , which is a F(ab′)2 fragment.
113 . The antigen-binding protein of claim 4 , which is a F(ab′)2 fragment.
114 . The antigen-binding protein of claim 8 , which is a F(ab′)2 fragment.
115 . The antigen-binding protein of claim 9 , which is a F(ab′)2 fragment.
116 . The antigen-binding protein of claim 13 , which is a F(ab′)2 fragment.
117 . The antigen-binding protein of claim 14 , which is a F(ab′)2 fragment.Join the waitlist — get patent alerts
Track US2023159656A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.